Motifast

Description

Motifast Tablet (Domperidone)

Manufacturer: Square Pharmaceuticals Ltd. Generic Name: Domperidone

Indications: Motifast Tablet is used to treat a variety of conditions, including:

• Nausea and Vomiting (including that associated with gastroparesis)
• Non-Ulcer Dyspepsia
• Gastritis
• Migraine (for symptomatic relief of nausea and vomiting)
• Lactation (to promote milk production, though its use for this indication should be carefully considered and discussed with a healthcare professional)

Dosage and Administration:

Motifast Tablet should be taken on an empty stomach, preferably 15-30 minutes before meals.

Adults (Oral):

• Nausea and Vomiting: 10-20 mg every 4-8 hours. Maximum dose: 80 mg/day.
• Non-Ulcer Dyspepsia: 10 mg three to four times daily. Maximum dose: 20 mg three to four times daily. The last dose should be taken at bedtime.
• Migraine: 20 mg every 4 hours. Maximum: 4 doses per 24 hours.

Adults (Rectal):

• Nausea and Vomiting: 60 mg twice daily.

Elderly:

• No dosage adjustment is typically needed.

Hepatic Impairment:

• No dosage adjustment is typically needed.

Children (Oral):

• 0.2 – 0.4 mg/kg every 4-8 hours daily.

Children (Rectal):

• <12 years and >15 kg: 30 mg twice daily.
• >12 years and >35 kg: 60 mg twice daily.

Renal Impairment:

• Mild to Moderate: No dosage adjustment is typically needed.
• Severe: Dosing should be reduced to 1-2 times daily with prolonged treatment.

Contraindications:

• Hypersensitivity to domperidone or any component of the formulation.
• Gastrointestinal hemorrhage, mechanical obstruction, or perforation.
• Patients with prolactin-releasing pituitary tumors.
• Chronic administration or routine prophylaxis of postoperative nausea and vomiting.

Precautions:

• Use with caution in patients with pheochromocytoma due to the risk of hypertensive crisis.
• Use with caution in children younger than 2 years.
• Exercise caution in elderly patients and those with renal or hepatic impairment.
• Intravenous administration carries a risk of cardiac arrhythmias and hypokalemia.
• Pregnancy and Lactation: Use during pregnancy and lactation should be carefully considered and discussed with a healthcare professional.

Interactions:

• May antagonize the hypoprolactinemic effect of bromocriptine.
• Opioid analgesics and antimuscarinics may antagonize the prokinetic effect of domperidone.
• Potentially Fatal: Concomitant use with potent CYP3A4 inhibitors (e.g., ketoconazole, erythromycin, ritonavir) may significantly increase serum domperidone levels, raising the risk of QT prolongation and serious cardiac arrhythmias.

Adverse Effects:

• Common: Drowsiness, extrapyramidal reactions, galactorrhea, gynecomastia, constipation or diarrhea, lassitude, decreased libido, skin rash, itching.
• Potentially Fatal/Serious: Convulsions, arrhythmias and cardiac arrest (especially in patients with pre-existing cardiovascular disease or hypokalemia, or those on cancer chemotherapy), seizures, hypertensive crisis (in patients with pheochromocytoma).

Mechanism of Action: Domperidone acts as a peripheral dopamine-receptor blocker. It enhances gastrointestinal motility by increasing esophageal peristalsis, improving gastroduodenal coordination, lowering esophageal sphincter pressure, and facilitating gastric emptying. This leads to a decrease in small bowel transit time.

Important Note: The information provided here for Motifast Tablet is for general knowledge and information purposes only, and does not constitute medical advice, diagnosis, or treatment. It is not intended to be a substitute for the exercise of professional medical judgment. Always consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.